DDInter1055 DDInter1077
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Liraglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Levofloxacin {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Liraglutide
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Levofloxacin (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Levofloxacin (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide